Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal down14.860 -0.440 (-2.876%)
Research Report

01/04/2020 15:51

{I-bank focus}CS lowers CSPC Pharma (01093) to HK$19.88

[ET Net News Agency, 1 April 2020] Credit Suisse lowered its target price for CSPC
Pharmaceutical (01093) to HK$19.88 from HK$21.91 and maintained its "outperform" rating.
The research house said CSPC's 4Q 2019 results missed Credit Suisse's expectations, due
to less-than-expected sales of common generics and bulk drugs and higher-than-expected
R&D spending.
Credit Suisse believes COVID-19 has a negative impact on the sales of most finished
drugs. It estimated sales to be dragged down by 6-8% for the whole year. But Credit Suisse
expects innovative drug sales to grow at 18% in 2020, driven by the continued quick growth
of NBP oncology drug sales.
In addition, the first batch GPO (group purchasing organization) would bring Rmb300mn
add-on sales of Clopidogrel. For the pipeline drugs, Credit Suisse expects two new drugs
to be launched and bring Rmb200 mn sales in 2020. (KL)

Remark: Real time quote last updated: 25/09/2020 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.